| 1 |
Asafo-Adjei T, Chen AJ, Najarzadeh A, et al. Advances in controlled drug delivery for treatment of osteoporosis [J]. Curr Osteoporos Rep, 2016, 14(5): 226-238.
|
| 2 |
Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments [J]. J Intern Med, 2019, 285(4): 381-394.
|
| 3 |
Tan J, Fu X, Sun CG, et al. A single CT-guided percutaneous intraosseous injection of thermosensitive simvastatin/poloxamer 407 hydrogel enhances vertebral bone formation in ovariectomized minipigs [J]. Osteoporos Int, 2016, 27(2): 757-767.
|
| 4 |
Ramachandran C, Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases [J]. Adv Drug Deliv Rev, 2000, 42(3): 197-223.
|
| 5 |
Lee CH, Kim H, Harburg DV, et al. Biological lipid membranes for on-demand, wireless drug delivery from thin, bioresorbable electronic implants [J]. NPG Asia Mater, 2015, 7(11): e227.
|
| 6 |
Wang H, Hu ZH, Chen L, et al. [Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis] [J]. Beijing Da Xue Xue Bao, 2016, 48(1): 680-682.
|
| 7 |
Jia Z, Zhang YJ, Chen YH, et al. Simvastatin prodrug micelles target fracture and improve healing [J]. J Control Release, 2015, 200: 23-34.
|
| 8 |
Posadowska U, Parizek M, Filova E, et al. Injectable nanoparticle-loaded hydrogel system for local delivery of Sodium alendronate [J]. Int J Pharm, 2015, 485(1/2): 31-40.
|
| 9 |
Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis [J]. J Am Acad Dermatol, 2018, 78(4): 733-740.e11.
|
| 10 |
Yun Y, Wu H, Gao J, et al. Facile synthesis of Ca(2+)-crosslinked Sodium alginate/graphene oxide hybrids as electro- and pH-responsive drug carrier [J]. Mater Sci Eng C Mater Biol Appl, 2020, 108: 110380.
|
| 11 |
Zhang KP, Ding CQ, Liu XL, et al. A redox and pH dual-triggered drug delivery platform based on chitosan grafted tubular mesoporous silica [J]. Ceram Int, 2019, 45(17): 22603-22609.
|
| 12 |
Ding C, Wu H, Yin ZZ, et al. Disulfide-cleavage- and pH-triggered drug delivery based on a vesicle structured amphiphilic self-assembly [J]. Mater Sci Eng C Mater Biol Appl, 2020, 107: 110366.
|
| 13 |
Smith JR, Lamprou DA. Polymer coatings for biomedical applications:a review [J]. Transactions of the IMF, 2014, 92(1): 9-19.
|
| 14 |
Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite [J]. Bone, 2006, 38(5): 617-627.
|
| 15 |
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice [J]. Mayo Clin Proc, 2008, 83(9): 1032-1045.
|
| 16 |
Wang H, Xiao L, Tao J, et al. Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice [J]. Pharmaceutics, 2018, 10(3): 154-164.
|
| 17 |
Bulman PC,Jonathan PM,Mansfield I,et al.Synthesis of bone-targeted oestrogenic compounds for the inhibition of bone resorption [J]. Tetrahedron, 2001, 57(9): 1837-1847.
|
| 18 |
Bhandari KH, Newa M, Uludag H, et al. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin [J]. Int J Pharm, 2010, 394(1/2): 26-34.
|
| 19 |
Hirabayashi H, Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS) [J]. J Control Release, 2001, 70(1/2): 183-191.
|
| 20 |
Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance [J]. Microbiol Mol Biol Rev, 2001, 65(2): 232-260; second page, table of contents.
|
| 21 |
Luginbuehl V, Meinel L, Merkle HP, et al. Localized delivery of growth factors for bone repair [J]. Eur J Pharm Biopharm, 2004, 58(2): 197-208.
|
| 22 |
Yamashita S, Katsumi H, Hibino N, et al. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases [J]. J Control Release, 2017, 262(262): 10-17.
|
| 23 |
Yun YH, Lee BK, Park K. Controlled drug delivery: historical perspective for the next Generation [J]. J Control Release, 2015, 219: 2-7.
|
| 24 |
Nafee N, Zewail M, Boraie N. Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis [J]. J Drug Target, 2018, 26(7): 563-575.
|
| 25 |
Bae J, Park JW. Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model [J]. Int J Pharm, 2015, 480(1/2): 37-47.
|
| 26 |
Lin K, Xia L, Li H,et al.Enhanced osteoporotic bone regeneration by strontium-substituted calcium silicate bioactive ceramics [J]. Biomaterials, 2013, 34(38): 10028-10042.
|
| 27 |
Muller M, Vehlow D, Torger B, et al. Adhesive drug delivery systems based on polyelectrolyte complex nanoparticles (PEC NP) for bone healing [J]. Curr Pharm Des, 2018, 24(13): 1341-1348.
|
| 28 |
Wang D, Miller S C, Kopečková P, et al. Bone-targeting macromolecular therapeutics[J]. Adv Drug Deliv Rev, 2005, 57(7): 1049-1076.
|
| 29 |
Razavi M, Fathi M, Savabi O, et al. In vivo biocompatibility of Mg implants surface modified by nanostructured merwinite/PEO [J]. J Mater Sci Mater Med, 2015, 26(5): 184.
|